ZYMEZymeworks Inc
Earnings Recap
• Reported GAAP EPS of -$0.55 down -77.42% YoY • Reported revenue of $2.52M down -91.90% YoY • Zymeworks expects approximately $300M in adjusted gross operating expenditures (non-GAAP) over three years ending December 31, 2028. Zymeworks anticipates cash resources, including $440M in milestones, to fund operations beyond 2028.
Bullish
Zymeworks saw significant revenue growth and reduced net loss in 2025. Non-dilutive financing extends Zymeworks' cash runway beyond 2028, while key product candidates advance towards regulatory approvals and substantial milestone payments.
Bearish
Zymeworks faces decreasing development-support revenue and a decline in other income due to reduced cash. Zymeworks' reliance on partners for key product advancement introduces operational and timing risks.